Evidence map›Paper›PMID 36288729›Full record

ArticleAmerican journal of human genetics2022

A founder event causing a dominant childhood epilepsy survives 800 years through weak selective pressure.

Bronwyn E Grinton, Erandee Robertson, Liam G Fearnley, Ingrid E Scheffer, Anthony G Marson, Terence J O'Brien, W Owen Pickrell, Mark I Rees, Sanjay M Sisodiya, David J Balding and 4 more

Open access · greenAbstract read
In one paragraph

Article in American journal of human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Identification of five novelFrontiers in behavioral neuroscience · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Bronwyn E GrintonEpilepsy Research Centre, Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC 3084, Australia.
Erandee RobertsonPopulation Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
Liam G FearnleyPopulation Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
Ingrid E SchefferEpilepsy Research Centre, Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC 3084, Australia; Department of Paediatrics, The University of Melbourne, Royal Children's Hospital, Parkville, VIC 3052, Australia; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC 3052, Australia; Florey Institute of Neuroscience and Mental Health, Heidelberg, VIC 3084, Australia.
Anthony G MarsonDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3BX, UK.
Terence J O'BrienDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neurology, The Royal Melbourne Hospital, Parkville, VIC 3052, Australia; Department of Neurology, Alfred Health, Melbourne, VIC 3004, Australia; Department of Medicine, The University of Melbourne, Parkville, VIC 3010, Australia.
W Owen PickrellSwansea University Medical School, Swansea University, Swansea SA2 8PP, UK; Department of Neurology, Morriston Hospital, Swansea Bay University Health Board, Swansea SA2 8PP, UK.
Mark I ReesSwansea University Medical School, Swansea University, Swansea SA2 8PP, UK; Faculty of Medicine & Health, University of Sydney, Camperdown, NSW 2006, Australia.
Sanjay M SisodiyaChalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire HP11 2FZ, UK; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
David J BaldingMelbourne Integrative Genomics, School of BioSciences and School of Mathematics & Statistics, University of Melbourne, Parkville, VIC 3010, Australia.
Mark F BennettEpilepsy Research Centre, Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC 3084, Australia; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
Melanie BahloPopulation Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
Samuel F BerkovicEpilepsy Research Centre, Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC 3084, Australia. Electronic address: s.berkovic@unimelb.edu.au.
Karen L OliverEpilepsy Research Centre, Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC 3084, Australia; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
The University of Melbourne · AUNational Hospital for Neurology and Neurosurgery · GBRoyal Children's Hospital · AUSwansea Bay University Health Board · GBThe Royal Melbourne Hospital · AUThe University of Sydney · AUUniversity of Liverpool · GB

Funding

Medical Research Council MC_PC_17228Medical Research Council MC_QA137853
6 · The paper itself

Abstract

Genetic epilepsy with febrile seizures plus (GEFS+) is an autosomal dominant familial epilepsy syndrome characterized by distinctive phenotypic heterogeneity within families. The SCN1B c.363C>G (p.Cys121Trp) variant has been identified in independent, multi-generational families with GEFS+. Although the variant is present in population databases (at very low frequency), there is strong clinical, genetic, and functional evidence to support pathogenicity. Recurrent variants may be due to a founder event in which the variant has been inherited from a common ancestor. Here, we report evidence of a single founder event giving rise to the SCN1B c.363C>G variant in 14 independent families with epilepsy. A common haplotype was observed in all families, and the age of the most recent common ancestor was estimated to be approximately 800 years ago. Analysis of UK Biobank whole-exome-sequencing data identified 74 individuals with the same variant. All individuals carried haplotypes matching the epilepsy-affected families, suggesting all instances of the variant derive from a single mutational event. This unusual finding of a variant causing an autosomal dominant, early-onset disease in an outbred population that has persisted over many generations can be attributed to the relatively mild phenotype in most carriers and incomplete penetrance. Founder events are well established in autosomal recessive and late-onset disorders but are rarely observed in early-onset, autosomal dominant diseases. These findings suggest variants present in the population at low frequencies should be considered potentially pathogenic in mild phenotypes with incomplete penetrance and may be more important contributors to the genetic landscape than previously thought.

Indexed as

EpilepsySeizures, FebrileChildElectroencephalographyHumansPedigreePhenotypeautosomal dominantchildhood-onset diseaseepilepsyfounder eventgeneticshaplotypes

Identifiers

PMID36288729
PMCPMC9674963
OpenAlexW4307404349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.